Isabelle C. Van Gelder, M.D., Hessel F. Groenveld, M.D., Harry J.G.M. Crijns,
M.D., Ype S. Tuininga, M.D., Jan G.P. Tijssen, Ph.D., A. Marco Alings,
M.D., Hans L. Hillege, M.D., Johanna A. Bergsma-Kadijk, M.Sc., Jan H. Cornel,
M.D., Otto Kamp, M.D., Raymond Tukkie, M.D., Hans A. Bosker, M.D., Dirk
J. Van Veldhuisen, M.D., Maarten P. Van den Berg, M.D., for the RACE II
Investigators
Lenient versus Strict Rate Control in Patients with Atrial Fibrillation
N Engl J Med. 2010 Apr 15;362(15):1363-73.
PubMed PMID: 20231232
カテゴリー: 予防 研究デザイン: ランダム化比較試験,非劣性試験 資金源: Netherlands Heart Foundation (2003B118),unrestricted educational grants
from AstraZeneca, Biotronik, Boehringer Ingelheim, Boston Scientific, Medtronic,
Roche, and Sanofi Aventis France (paid to the Interuniversity Cardiology
Institute of the Netherlands). 利益相反: Dr. Van Gelder reports receiving consulting fees from Sanofi-Aventis,
Boehringer Ingelheim, and Cardiome, grant support from Medtronic, Biotronik,
and St. Jude Medical, and lecture fees from Sanofi-Aventis, Boehringer
Ingelheim, and Medtronic; Dr. Crijns, consulting fees from Boehringer Ingelheim,
Sanofi-Aventis, and AstraZeneca, grant support from St. Jude Medical, Boston
Scientific, Boehringer Ingelheim, Sanofi-Aventis, Medapharma, and Merck,
and honoraria from Medtronic, Sanofi-Aventis, Medapharma, Merck, Boehringer
Ingelheim, and Biosense Webster; Dr. Alings, consulting fees from Boehringer
Ingelheim and Sanofi-Aventis; and Dr. Van Veldhuisen, board membership
fees from Amgen and Pfizer, consulting fees from Medtronic, Biotronik,
and Biosite-Inverness, lecturefees from Merck, Menarini, and Medtronic,
and travel reimbursement from Pfizer. No other potential conflict of interest
relevant to this article was reported.